Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Rituximab 9fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Cyclophosphamide 7Whole-Body Irradiation 4Radiotherapy 4Bendamustine Hydrochloride 4Mycophenolic Acid 3Filgrastim 3Cytarabine 3ibrutinib 2fludarabine 2duvelisib 2Tacrolimus 2Pentostatin 2Pentetic Acid 2Methotrexate 2Melphalan 2Lenalidomide 2Etoposide 2Dexamethasone 2Cyclosporine 2Cord Blood Stem Cell Transplantation 2Carmustine 2umbralisib 1ublituximab 1tetulomab tetraxetan lu-177 1sargramostim 1romidepsin 1parsaclisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, B-Cell, Marginal Zone × obatoclax × Clear all
NCT01238146 2013-06-06

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡